Who is sponsoring NCT02018679?

NCT02018679 is sponsored by Dong-A University.

What condition does NCT02018679 study?

NCT02018679 studies Nodular Basal Cell Carcinoma.

What drugs are being tested in NCT02018679?

Interventions: Er:YAG AFL-PDT, MAL-PDT.

What is the status of NCT02018679?

NCT02018679 is currently COMPLETED.

Last reviewed 2013-12-17 · How we verify

Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Nodular Basal Cell Carcinoma in Asian: A Prospective, Randomized Study With 12 Months Follow-up

NCT02018679 Phase 1 COMPLETED

Topical photodynamic therapy with methyl-aminolaevulinate (MAL-PDT) has been introduced as an alternatively attractive procedure for BCC. Er:YAG ablative fractional laser (AFL) treatment removes the stratum corneum to increase MAL uptake and may improve efficacy. However, no studies have directly compared the efficacy of Er:YAG AFL-PDT and MAL-PDT in treating nodular BCC in Asians.

Details

Lead sponsor	Dong-A University
Phase	Phase 1
Status	COMPLETED
Enrolment	34
Start date	2011-03
Completion	2013-09

Conditions

Nodular Basal Cell Carcinoma

Interventions

Er:YAG AFL-PDT
MAL-PDT

Primary outcomes

Difference the efficacy between Er:YAG AFL-PDT and MAL-PDT — Efficacy was evaluated at 3 months and 12 months after treatment
Lesion responses were classified as either a complete response (complete disappearance of the lesion) or a non-complete response (incomplete disappearance)

Countries

South Korea